Nanoemulsions as medicinal components in insoluble medicines

Background: Medicine’s success relies on solubility, which is the process of dissolving a solid substance in a fluid phase to create a uniform molecular dispersion. However, hydrophobic active medicinal components exhibit poor solubility in water, limiting their effectiveness and incorporation into medications. Aim: This review explores the potential of nanoemulsions as a solution for delivering hydrophobic medicinal components with low solubility. The study investigates the benefits of nanoemulsions, including enhanced absorption, effective targeting, controlled release, and protection of encapsulated bioactive ingredients. Materials and methods: Nanoemulsions are formulated by combining two immiscible liquids with emulsifying agents within a thermodynamically stable colloidal dispersion system. The review categorizes various preparation techniques into high-energy and low-energy spontaneous emulsification methods. The choice of preparation procedures and materials used significantly affects the stability of nanoemulsions over time. Evaluation of nanoemulsions includes studying medication release in vitro, in vitro permeation, stability and thermodynamic stability, shelf life, viscosity, interfacial tension, pH, and osmolarity. Results: Nanoemulsions, such as Celecoxib (Phase Inversion), acetylsalicylic acid (Ultrasonication), and Flurbiprofen (Homogenization and Ultrasonication), offer distinct advantages for medications with low solubility compared to conventional emulsions. These nanoemulsions comprise small droplets with a larger surface area, promoting enhanced absorption. They demonstrate effective targeting, controlled release, and protection of encapsulated bioactive ingredients. Moreover, the diminutive droplet sizes of nanoemulsions contribute to their reduced susceptibility to issues like flocculation, coalescence, sedimentation, or creaming. Conclusion: Nanoemulsions hold great promise in overcoming the solubility limitations of hydrophobic medicinal components. They provide enhanced absorption, effective targeting, controlled release, and protection of bioactive ingredients. The choice of preparation techniques and materials plays a crucial role in ensuring the stability of nanoemulsions over time. Further studies are warranted to optimize their use and explore their potential applications in drug delivery systems

The relationship between statin therapy and adipocytokine/inflammatory mediators in dyslipidemic nondiabetic patients: A comparative study

Background: Statins have emerged as a vital therapeutic option for dyslipidemia, effectively reducing morbidity and mortality in individuals with various medical conditions. Recent research has shed light on the intricate pathophysiology of atherosclerosis, which involves lipid accumulation and inflammatory mediators. This research was conducted to assess the correlation between statin therapy and adipocytokine and inflammatory mediator levels in dyslipidemic nondiabetic patients. Methods: A total of 67 dyslipidemic nondiabetic patients were enrolled, alongside 33 healthy controls. The participants were categorized into three groups: Group (A), comprising patients undergoing statin therapy (n = 34), Group (B), consisting of patients not receiving statin therapy (n = 33); and Group (C), comprising healthy controls (n = 33). Results: Patients not receiving statin therapy exhibited significant dyslipidemic profiles compared to patients undergoing statin therapy and healthy controls. Levels of total cholesterol (TC), triglycerides (TG), very low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) were higher in patients not receiving statin therapy. Serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) were higher in the statin group than in the non-statin group and controls. Additionally, PCSK9 levels were higher in patients treated with rosuvastatin than those treated with atorvastatin. Conversely, levels of retinol-binding protein 4 (RBP4) were lower in the statin group compared to the non-statin group and controls. Although no significant difference in RBP4 levels between atorvastatin and rosuvastatin users was found, atorvastatin displayed lower RBP4 values. The study also revealed lower C-reactive protein (CRP) levels in the statin group, primarily in the rosuvastatin subgroup, compared to the non-statin group. Conclusion: Statin therapy increased PCSK9 levels, with a more pronounced rise observed in patients treated with rosuvastatin than atorvastatin. Statin therapy proved protective by reducing RBP4 and CRP levels in dyslipidemic nondiabetic patients

Phytochemical analysis and GC-MS-MS investigation of methanol extract of Calotropis procera aerial parts

The purpose of our study was to examine chemical constituents of Calotropis Procera aerial parts using preliminary chemical test and GC-MS-MS analysis  since no  enough phytochemical investigation had been done regarding the plant in Iraq, the aerial parts leaves stems and fruits  of C. Procera were extracted  in 95% aqueous methanol in soxhlet  and fractionated with n-hexane , chloroform respectively . The extract was analyzed using specific chemical reactions to diagnose the chemicals specifically the important secondary metabolites, and then checked further in GC-MSMS to identify the identity of each compound

The relationship between statin therapy and adipocytokine/inflammatory mediators in dyslipidemic nondiabetic patients: A comparative study

Background: Statins have emerged as a vital therapeutic option for dyslipidemia, effectively reducing morbidity and mortality in individuals with various medical conditions. Recent research has shed light on the intricate pathophysiology of atherosclerosis, which involves lipid accumulation and inflammatory mediators. This research was conducted to assess the correlation between statin therapy and adipocytokine and inflammatory mediator levels in dyslipidemic nondiabetic patients. Methods: A total of 67 dyslipidemic nondiabetic patients were enrolled, alongside 33 healthy controls. The participants were categorized into three groups: Group (A), comprising patients undergoing statin therapy (n = 34), Group (B), consisting of patients not receiving statin therapy (n = 33); and Group (C), comprising healthy controls (n = 33). Results: Patients not receiving statin therapy exhibited significant dyslipidemic profiles compared to patients undergoing statin therapy and healthy controls. Levels of total cholesterol (TC), triglycerides (TG), very low-density lipoprotein (VLDL), and low-density lipoprotein (LDL) were higher in patients not receiving statin therapy. Serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) were higher in the statin group than in the non-statin group and controls. Additionally, PCSK9 levels were higher in patients treated with rosuvastatin than those treated with atorvastatin. Conversely, levels of retinol-binding protein 4 (RBP4) were lower in the statin group compared to the non-statin group and controls. Although no significant difference in RBP4 levels between atorvastatin and rosuvastatin users was found, atorvastatin displayed lower RBP4 values. The study also revealed lower C-reactive protein (CRP) levels in the statin group, primarily in the rosuvastatin subgroup, compared to the non-statin group. Conclusion: Statin therapy increased PCSK9 levels, with a more pronounced rise observed in patients treated with rosuvastatin than atorvastatin. Statin therapy proved protective by reducing RBP4 and CRP levels in dyslipidemic nondiabetic patients

Memantine and its role in parkinsonism, seizure, depression, migraine headache, and Alzheimer’s disease

Alzheimer’s disease (AD) is a neurological disorder characterized by mental and behavioral changes that develop progressively with a decline in brain function. Dysfunctions in glutamatergic and cholinergic pathways, along with an increased concentration of beta-amyloid protein (Aβ), lead to synapses that are full of phosphorylated protein. These changes result in several pathological, biochemical, cellular, and molecular alterations that increase neural excitation directly or indirectly at the neural level, affecting the synapse, axons, signal transmission, and all parts of neurons. All these alterations, with continuous excitatory effects, eventually lead to neural loss and degradation due to stimulation of the immune response. However, memantine is a non-competitive antagonist of N-methyl-D-aspartic acid (NMDA) glutamatergic receptors of moderate affinity and voltage-dependent that blocks the effects of pathologically elevated glutamate tonic levels, which can lead to neuronal dysfunction. Memantine has shown improvement in cognition, global clinical status, activities of daily living, and behavioral disturbances in moderate and severe AD. In this review, we will discuss the effects of memantine use and side effects, as well as its application in treating other diseases or pathological conditions with the prospective use of memantine or an alternative. Memantine is generally well-tolerated, and the most common adverse reactions are vertigo, headache, and hallucinations, which are usually mild